Showing posts with label ulcerative colitis. Show all posts
Showing posts with label ulcerative colitis. Show all posts

Tuesday, December 18, 2018

Another Day of Me and Maybe More?

Originally this blog was started to help me process every thing I was going through with my stem cell transplant. Then after it all calmed down, i stopped writing. I automatically assumed I had nothing anyone would want to hear.

Im learning now, I need to write for me and in the process, I hope someone reads and relates. My greatest wish is that someone can learn from my journey, from my pain, and it can help them. We all know Crohn's doesn't just affect the body, but it alters the mind as well. Sometimes all we need is someone else who gets it. You know, REALLY GETS IT!

I hope that as I start back writing more often, God will give me the words that you may need to hear.

As for today, remember you are special and loved. Crohnies United!

Sunday, January 24, 2016

Camera Endoscopy aka Pill Cam

Pill Cam Endoscopy
Information via Mayo Clinic

Definition:

Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.

Capsule endoscopy helps doctors see inside your small intestine — an area that isn't easily reached with more-traditional endoscopy procedures. Traditional endoscopy involves passing a long, flexible tube equipped with a video camera down your throat or through your rectum.

Capsule endoscopy has also been approved for the screening of the colon for colon polyps for those for whom a colonoscopy couldn't be completed. But how and on whom it will be used is still being determined because better alternatives are available. As technology improves, capsule endoscopy of the colon may be used more in the future.

Capsule endoscopy has also been approved to evaluate the muscular tube that connects your mouth and your stomach (esophagus) to look for abnormal, enlarged veins (varices). It's rarely used because experience with it is limited and traditional upper endoscopy is widely available.

Why It's Done:

Your doctor might recommend a capsule endoscopy procedure to:

Find the cause of gastrointestinal bleeding.If you have unexplained bleeding in your digestive tract, capsule endoscopy can help find the cause.Diagnose inflammatory bowel diseases, such as Crohn's disease. Capsule endoscopy can reveal areas of inflammation in the small intestine.Diagnose cancer. Capsule endoscopy can show tumors in the small intestine or other parts of the digestive tract.Diagnose celiac disease. Capsule endoscopy is sometimes used in diagnosing and monitoring this immune reaction to eating gluten.Screen for polyps. People who have inherited syndromes that can cause polyps in the small intestine might occasionally undergo capsule endoscopy.Do follow-up testing after X-rays or other imaging tests. If results of an imaging test are unclear or inconclusive, your doctor might recommend a capsule endoscopy to get more information.

Risks:

Capsule endoscopy is a safe procedure that carries few risks. However, it's possible for a capsule to become lodged in the digestive tract rather than leaving your body in a bowel movement within several days.

The risk, which is small, might be higher in people who have a condition — such as a tumor, Crohn's disease or previous surgery in the area — that causes a narrowing (stricture) in the digestive tract. If you have abdominal pain or are at risk of a narrowing of your intestine, your doctor likely will get a CT scan to look for a narrowing before using capsule endoscopy. Even if the imaging study is negative, there's still a small chance that the capsule could get stuck.

If the capsule hasn't passed in a bowel movement but isn't causing signs and symptoms, your doctor might give the capsule more time to leave your body. However, a capsule causing signs and symptoms that indicate bowel obstruction must be removed, either by surgery or through a traditional endoscopy procedure, depending on where the capsule is stuck.

How To Prepare :

To prepare for your capsule endoscopy, your doctor is likely to ask that you:

Stop eating and drinking at least 12 hours before the procedure. This will ensure that the camera captures clear images of your digestive tract.Stop or delay taking certain medications.To keep medication from interfering with the camera, your doctor might ask you not to take certain medications before the procedure. In other cases, your doctor will want you to take your medication two hours before or after you swallow the camera capsule that contains the camera.Plan to take it easy for the day. In most cases, you'll be able to go about your day after you swallow the camera capsule. But you'll likely be asked not to do strenuous exercise or heavy lifting. If you have an active job, ask your doctor whether you can go back to work the day of your capsule endoscopy.

In some cases, your doctor may ask you to take a laxative before your capsule endoscopy to flush out your small intestine. This has been shown to improve the quality of the pictures collected by the capsule's camera.

Follow your doctor's instructions in preparing for your capsule endoscopy. Failure to follow the directions may mean your capsule endoscopy may need to be rescheduled.

What To Expect :

During capsule endoscopy

On the day of your capsule endoscopy, your health care team will review the procedure. You might be asked to remove your shirt so that adhesive patches can be attached to your abdomen. Each patch contains an antenna with wires that connect to a recorder. Some devices don't require the patches.

You wear the recorder on a special belt around your waist. The camera sends images to an antenna on your abdomen, which feeds the data to the recorder. The recorder collects and stores the images.

Once the recorder is connected and ready, you swallow the camera capsule with water. A slippery coating makes it easier to swallow. Once you swallow it, you shouldn't be able to feel it.

You'll then go about your day. You can drive, and you might be able to go to work, depending on your job. Your doctor will discuss restrictions, such as avoiding strenuous activity, such as running and jumping, with you.

After the capsule endoscopy

Wait two hours after you swallow the capsule to resume drinking clear liquids. After four hours, you can have a light lunch or a snack unless your doctor tells you otherwise.

The capsule endoscopy procedure is complete after eight hours or when you see the camera capsule in the toilet after a bowel movement, whichever comes first. Remove the patches and the recorder from your body, pack them in a bag and follow your doctor's instructions for returning the equipment. You can flush the camera capsule down the toilet.

Your body might expel the camera capsule within hours or after several days. Each person's digestive system is different. If you don't see the capsule in the toilet within two weeks, contact your doctor. Your doctor might order an X-ray to see if the capsule is still in your body.

Results:

The camera used in capsule endoscopy takes thousands of color photos as it passes through your digestive tract. The images saved on the recorder are transferred to a computer with special software that strings the images together to create a video. Your doctor watches the video to look for abnormalities within your digestive tract.

It might take a few days to a week or longer to receive the results of your capsule endoscopy. Your doctor will then share the results with you.

Friday, July 3, 2015

Crohn's VS Ulcerative Colitis

The Difference Between Crohn’s, UC, and IBD

Part 1 of 5

Many people are confused when it comes to the differences between inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis (UC). The short explanation is that IBD is the umbrella term for the condition under which both Crohn's disease and ulcerative colitis fall. But there is, of course, much more to the story.

Both Crohn’s and UC are marked by an abnormal response by the body’s immune system, and they may share some symptoms. However, there are important differences as well. These distinctions primarily include the location of the maladies in the gastrointestinal (GI) tract and the way each disease responds to treatment. Understanding these features is key to obtaining a proper diagnosis from a gastroenterologist.

Part 2 of 5

Inflammatory Bowel Disease

IBD was seldom seen before the rise of improved hygiene and urbanization at the beginning of the 20th century. Today, it’s still found mainly in developed countries such as the United States. Like other autoimmune and allergic disorders, it’s believed that a lack of germ resistance development has partly contributed to diseases such as IBD.

In people with IBD, the immune system mistakes food, bacteria, or other materials in the GI tract for foreign substances and responds by sending white blood cells into the lining of the bowels. The result of the immune system's attack is chronic inflammation. The word inflammation itself comes from the Greek word for flame. It literally means "to be set on fire."

Crohn’s and UC are the most common forms of IBD. Oftentimes, the terms are interchangeable. Less common IBDs include:

microscopic colitisdiverticulosis-associated colitiscollagenous colitislymphocytic colitisBehçet's disease.

IBD may strike at any age. According to theMayo Clinic, most people with IBD are diagnosed before the age of 30. It’s more common:

in urban areasamong people in higher socioeconomic bracketsindustrialized countriesnorthern climatesin Caucasians as opposed to darker-skinned people and those of Asian descentin people who eat high-fat diets

Aside from environmental factors, genetic factors are believed to play a strong role in the development of IBD. Therefore, it’s considered to be a "complex disorder.”

Unfortunately, there’s currently no cure for IBD. This is a lifelong disease, with alternating periods of remission and flare-up. Modern treatments, however, allow people to live relatively normal and productive lives.

IBD should not be confused with irritable bowel syndrome (IBS). IBS is a much less serious affliction than either Crohn’s disease or ulcerative colitis. It doesn’t involve inflammation or appear to have a physiological basis.

Part 3 of 5

Crohn’s Disease

Crohn’s disease may affect any part of the GI tract from the mouth to the anus, although it’s most often found at the end of the small intestine (small bowel) and the beginning of the colon (large bowel).

Symptoms of Crohn's disease include:

persistent diarrheacrampy abdominal painfeveroccasional rectal bleedingfatigue

Unlike with UC, Crohn's isn't limited to the GI tract. It may also affect the skin, eyes, joints, and liver. Since symptoms usually get worse after a meal, patients with Crohn's will often experience weight loss due to food avoidance.

Crohn's disease can cause blockages of the intestine due to scarring and swelling. Ulcers (sores) in the intestinal tract may develop into tracts of their own, known as fistulas. Crohn’s disease can also increase the risk for colon cancer, which is why patients must have regular colonoscopies.

Medication is the most common way to treat Crohn's disease. The five types of drugs are:

steroidsantibioticsimmune modifiers, such as azathioprine and 6-MPaminosalicylates, such as 5-ASAbiologic therapy

Some cases may also require surgery. Still, surgery will not cure Crohn’s disease.

Part 4 of 5

Unlike Crohn's, UC is confined to the colon (large bowel) and only affects the top layers in an even distribution. Symptoms of UC include:

crampy abdominal painloose stoolsbloody stoolurgent bowelfatigueloss of appetiteanemia due to blood loss (in severe cases only)

The symptoms of UC can also vary by type. According to the Mayo Clinic, there are five kinds of UC:

acute severe UC (a rare form that causes eating difficulties)left-sided colitis (affects descending colon and rectum)pancolitis (affects the whole colon and causes persistent bloody diarrhea)proctosigmoiditis (affects lower colon and rectum)ulcerative proctitis (mildest form that affects the rectum only)

With the exception of biologic therapy, treatments for the disease are the same as for Crohn's. Unlike with Crohn's, however, most patients with UC will almost never require surgery. 

Children with the disease may not develop or grow properly. Remission periods tend to be longer with UC than with Crohn's disease, and complications are far less frequent. Still, when complications do occur, they can be severe. Left untreated, UC may lead to:

holes in the coloncolon cancerliver diseaseosteoporosisblood clots

Part 5 of 5

Diagnosing IBD

There’s no doubt that IBD can significantly decrease quality of life, between uncomfortable symptoms and frequent bathroom visits. Even worse is the fact that IBD can lead to scar tissue, and even permanent damage. If you experience any unusual symptoms, it’s important to call a doctor. You may be referred to a gastroenterologist for IBD testing, such as a colonoscopy or a CT scan. Diagnosing the right form of IBD will lead to more effective therapies.

While there’s no cure for any form of IBD, early treatment and lifestyle changes can help minimize damage and complications. Treatment will also reduce the amount of symptoms.

Copyright © 2005 - 2015 Healthline Networks, Inc. All rights reserved for Healthline. Healthline is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations. Terms of Use |Privacy Policy

Saturday, February 14, 2015

Entyvio and Crohn’s Disease

FDA Approves Takeda’s Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

May 21, 2014

Deerfield, Ill., May 20, 2014, and Osaka, Japan, May 21, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

“Entyvio is a new option that works to block important contributors to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn’s disease,” said Stephen B. Hanauer, M.D., medical director, Digestive Health Center, Northwestern University Feinberg School of Medicine. “The clinical trial program evaluated the efficacy and safety profile of Entyvio and demonstrated that Entyvio has the potential to help adult patients with moderately to severely active UC or CD successfully manage their disease.”

Entyvio is now approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid-free remission in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. Entyvio is also approved for achieving clinical response and remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.

“Patients with moderately to severely active ulcerative colitis or Crohn’s disease, and the healthcare professionals who care for them, need additional new treatment options,” said Douglas Cole, president,
Takeda Pharmaceuticals U.S.A., Inc. “Entyvio reflects an expansion of Takeda’s commitment to supporting patients with gastrointestinal disorders.”
The Entyvio dose regimen is 300 mg infused intravenously over approximately 30 minutes at zero, two and six weeks, then every eight weeks thereafter. Patients should be observed during infusion and until the infusion is complete. See dosage and administration section in full prescribing information.

In March, Entyvio received a positive Opinion for the treatment of adults with moderately to severely active UC and CD from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and Takeda is awaiting response from the European Commission on approval for Marketing Authorisation.

Clinical Trial Program
The Biologics License Application filing with the FDA was supported by the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both UC and CD patient populations in four clinical studies involving 2,700 patients in nearly 40 countries. Three of these studies were randomized, double-blind, placebo-controlled trials – GEMINI I (UC Trials I and II), GEMINI II (CD Trials I and III) and GEMINI III (CD Trial II). GEMINI I, II and III evaluated adult patients with moderately to severely active UC or CD who had an inadequate response or intolerance to immunomodulator therapy; inadequate response, loss of response, or intolerance to a TNF blocker; or were corticosteroid dependent or had an inadequate response or intolerance to corticosteroids.

Adverse reactions were reported in 52 percent of patients treated with Entyvio and 45 percent of patients treated with placebo (UC Trials I and II: 49 percent with Entyvio and 37 percent with placebo; CD Trials I and III: 55 percent with Entyvio and 47 percent with placebo). Serious adverse reactions were reported in 7 percent of patients treated with Entyvio compared to 4 percent of patients treated with placebo (UC Trials I and II: 8 percent with Entyvio and 7 percent with placebo; CD Trials I and III: 12 percent with Entyvio and 9 percent with placebo).
The most common adverse reactions reported with Entyvio (incidence greater than or equal to 3 percent and greater than or equal to 1 percent higher than placebo) were nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.

About Entyvio™ (vedolizumab)

Entyvio, an integrin receptor antagonist, is a humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Entyvio does not bind to or inhibit function of the alpha4beta1 and alpha E beta 7 integrins and does not antagonize the interaction of alpha4 integrins with vascular cell adhesion molecule-1 (VCAM-1). The alpha4beta7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T-lymphocytes to gut lymph tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn’s disease.

INDICATIONS: ENTYVIO™ (vedolizumab)
Adult Ulcerative Colitis (UC)

Adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:
• inducing and maintaining clinical response
• inducing and maintaining clinical remission
• improving endoscopic appearance of the mucosa
• achieving corticosteroid-free remission
Adult Crohn's Disease (CD)

Adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids:
• achieving clinical response
• achieving clinical remission
• achieving corticosteroid-free remission

IMPORTANT SAFETY INFORMATION
• ENTYVIO (vedolizumab) is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
• Infusion-related reactions and hypersensitivity reactions including anaphylaxis have occurred. If anaphylaxis or other serious allergic reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
• Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections.
• Although no cases of PML have been observed in ENTYVIO clinical trials, JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death has occurred in patients treated with another integrin receptor antagonist. A risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
• There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
• Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.
• Most common adverse reactions (incidence greater than or equal to 3% and greater than or equal to 1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.
Please see the accompanying full Prescribing Information including Medication Guide for ENTYVIO.
More information will also be available soon at www.ENTYVIOHCP.com andwww.ENTYVIO.com.

©2015 Crohn's & Colitis Foundation of America

Tuesday, February 10, 2015

Low Residue Diet

I've been trying to diet and lose weight lately and I ended up losing sight of what I could and couldn't eat due to my Crohn's disease. I want to eat like everyone else trying to diet. Unfortunately,  eating raw veggies is just not a realistic plan and I ended up with a small bowel obstruction because of my poor choices. So I'm heading back towards a low residue/fiber diet and I wanted to share a bit of information for everyone!

Should You Try a Low-Residue Diet?

If a doctor has diagnosed you or a loved one with an inflammatory bowel disease (IBD) -- like Crohn's disease or ulcerative colitis -- or with diverticulitis, your doctor may suggest you follow a low-residue diet.

Never heard of it? The basic idea is that you'll eat foods that are easy to digest, and you'll limit those that aren't. 

What Is a Low-Residue Diet?

It's a diet that limits high-fiber foods, such as whole-grain breads and cereals, nuts, seeds, raw or dried fruits, and vegetables.

New Way to Ease Ulcerative Colitis?

"Residue" refers to undigested food, including fiber, that make up stool. The goal of the diet is to have fewer, smaller bowel movements each day, in order to ease symptoms such as diarrhea, bloating, gas, and stomach cramping.

Your doctor may recommend that you go on a low-residue diet for a short time when you're having a flare, or after surgery to help with recovery. But it's not a general eating plan for all people with IBD. 

Crohn's can make it harder for your body to absorb nutrients from food. Ask your doctor for a referral to a nutritionist who can make sure your diet plan is right for you and let you know if you need any vitamin supplements.

On a low-residue diet, you can eat:

Grains

Refined or enriched white breads and plain crackers, such as saltines or Melba toast (no seeds)Cooked cereals, such as farina, cream of wheat, and gritsCold cereals, such as puffed rice and corn flakesWhite rice, noodles, and refined pasta

Fruits and Vegetables

The skin and seeds of many fruits and vegetables are loaded with fiber, so peeling skin and avoiding seeds is part of a low-residue diet. You can eat the following vegetables on the diet:

Well-cooked fresh vegetables or canned vegetables without seeds, such as asparagus tips, beets, green beans, carrots, mushrooms, spinach, squash (no seeds), and pumpkinCooked potatoes without skinTomato sauce (no seeds)

Fruits include:

Ripe bananasSoft cantaloupeHoneydewCanned or cooked fruits without seeds or skin, such as applesauce or canned pearsAvocado

Milk and Dairy

Milk products are OK to eat in moderation. Milk has no fiber, but it may trigger symptoms such as diarrhea and cramping if you have lactose intolerance. You could use lactase supplements or eat lactose-free products.

Reviewed by Jennifer Robinson, MD on November 18, 2014

© 2014 WebMD, LLC. All rights reserved.

Friday, January 30, 2015

Donate Your Stool?? Healthy People Only

You can earn $13,000 a year selling your poop

By Rachel Feltman January 29 

You can donate blood, plasma, eggs, and sperm. Why not poop? Yes, your feces are perhaps your greatest untapped monetary resource. Thanks to a nonprofit organization called OpenBiome, you can cash in to the tune of $13,000 a year -- and save lives while you're at it.

Since 2013, OpenBiome has been processing and shipping loads of it all over the country. The frozen stool is administered to patients who are very sick with infections of a bacteria called C. difficile. The bacteria can cause extreme gastrointestinal distress, leaving some sufferers housebound. Antibiotics often help, but sometimes the bacteria rears back as soon as treatment stops. That leads to a miserable, continuous course of antibiotics.

By introducing healthy fecal matter into the gut of a patient (by way of endoscopy, nasal tubes, or swallowed capsules) doctors can abolish C. difficile for good. Finding a donor is tough business, and some patients grow so desperate that they treat themselves with fecal matter from friends and family. That's what happened to a friend of OpenBiome's founders, inspiring them to open up the first nationwide bank. So far they've shipped about 2,000 treatments to 185 hospitals around the country.

And yes, they pay for healthy poop: $40 a sample, with a $50 bonus if you come in five days a week. That's $250 for a week of donations, or $13,000 a year.

Save your stools, save the world. (OpenBiome)
There's a catch: You don't just have to be healthy. You have to be really healthy. OpenBiome's donation procedure may be as easy as your standard bowel movement, but the selection process makes giving blood look like a walk in the park.

"It's harder to become a donor than it is to get into MIT," joked co-founder Mark Smith (who would know, as he got his PhD in microbiology there). Of the 1,000 or so potential donors who've expressed interest on his Web site over the past two years, only about 4 percent have passed the extensive medical questioning and stool testing.

The screening process can cost up to $5,000 -- so when someone makes it through, Smith and his co-founders hold on tight.

"We get most of our donors to come in three or four times a week, which is pretty awesome," Smith said. "You're usually helping three or four patients out with each sample, and we keep track of that and let you know."


The precious poo awaits its destiny at -80 celsius. (OpenBiome)
Fellow co-founder Carolyn Edelstein agrees that the donors are usually in it for more than the money.

"Everyone thinks it's great that they're making money doing such an easy thing," Edelstein said, "But they also love to hear us say, 'Look, your poop just helped this lady who's been sick for nine years go to her daughter's graduation.'"

Who are these valiant donors, these chosen few? Since they have to come into the Medford, Mass. office, lots of them are Tufts University students. And plenty are recruited from the gym next door.

"It's great to have a healthy contingent of regular gym goers right there," Smith said.


OpenBiome has sent out more than 2,000 transplant specimens. (OpenBiome)
For now fecal matter transplants really only have one use: treating recurring C. difficile. But OpenBiome is providing its samples to a number of trials exploring other uses.

Scientists know that the gut microbiomes of people with obesity, inflammatory bowel disease, and even autism are different from those without. But just because there are gut flora associated with these conditions doesn't mean that getting rid of them can get rid of their symptoms, and it certainly isn't a given that fecal transplants will be the miracle solution they are for  C. difficile.

"There's a lot of promise in other conditions," Smith said, "But also a lot of hype. Treating C. difficile is a bit less sexy, but that's the one area where we know this works." However, he's excited to see where the "crazy frontier" of microbiome engineering will take us.

And in the meantime, Smith is always happy to find more potential donors.

"I never thought that after getting my PhD I'd start mailing poop around," he said, "But here I am."


 

Fecal Transplant Study As A Possible Cure

Inflammatory Bowel Disease 'Cured' With Fecal Transplant

January 22, 2015 5:06 PM
By Jessica Berman

Inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are extremely painful and can lead to colorectal cancer. Now, researchers have effectively cured the conditions in mice, offering hope for human sufferers of so-called IBDs.

Waste material from healthy people is rich in helpful bacteria. When transferred to the digestive tracts of sick individuals, in whom there is an overgrowth of bad bacteria, the fecal matter helps restore the balance of healthy flora.

Some cutting-edge doctors have used so-called fecal transplants to treat severe bacterial infections, including Clostridium difficile or C. diff, which releases toxins as it grows, attacking the lining of the intestines.

Scientists also have found the transplants appear to reverse autoimmune diseases of the bowel.

Crohn’s disease and ulcerative colitis, also known as inflammatory bowel disease or IBD, are life-long disorders that cause severe diarrhea, painful cramps and bleeding.

According to June Round, a professor of medicine at the University of Utah, such diseases are becoming increasingly common around the world, as more and more people eat a low-fiber, high-fat Western diet.

Round also blames the widespread use of antibiotics.

“So, I think a lot about the microbes that naturally reside in our bodies. And antibiotics can not distinguish between what is good and what is bad," she said. "They kind of wipe-out everything. So, there is a very clear-cut correlation between when Western civilization started using the antibiotics and the increased incidence of a lot of these autoimmune diseases.”

Currently, treatments for these conditions are supportive, designed only to ease the symptoms. So, the idea of a potential cure for IBD is very appealing.

In experiments with mice with inflammatory bowel disease, Round and her team found that fecal transplant restored the healthy balance of intestinal flora, returning the intestine to near normal.

But the notion of transferring fecal material from one person to another -- and in the case of mice, through a tube into the stomach -- makes many people say "yuck." So Round said researchers are now trying to identify the helpful bacteria in human waste so they can be put into pill form.

“You know, right now we have to do fecal transplantation because the [bacterial] communities are so complex, and we just do not know what organisms are doing the good thing," she said. "So, we just kind of put it all in there and hope for the best. So, there is no way of getting around it right now, but hopefully in the future there will be.”

The work is published in the journal Cell Host and Microbe.

Wednesday, January 28, 2015

Just A Thought

I was just on a Crohn's Facebook page and I was looking at the different issues we, as crohnies, face and how the world sees us. I've discovered that we can be quite the performers.  Everyday we deal with pain, urgency,  accidents, anxiety, illness, and so many other things and yet we hear all the time how great we look. Well, for one, the disease is in our gut, not our face. Secondly, we are incredible actors. Somehow we manage to get up and get out and live the same life as everyone else...in a outer appearance kind of way. Our bodies may get weak, but our spirits are strong. We handle the cards we've been dealt, smile, and live the best we know how.

Sunday, November 9, 2014

Psychological Issues in IBD


Gastroenterology Research and Practice

Volume 2012 (2012), Article ID 106502, 11 pages
http://dx.doi.org/10.1155/2012/106502

Psychological Issues in Inflammatory Bowel Disease: An Overview

M. S. Sajadinejad,1 K. Asgari,1 H. Molavi,1 M. Kalantari,1 and P. Adibi2

Abstract

Inflammatory bowel disease (IBD) including Crohn’s disease (CD) and ulcerative colitis (UC) is a chronic and disabling disease with unknown etiology. There have been some controversies regarding the role of psychological factors in the course of IBD. The purpose of this paper is to review that role. First the evidence on role of stress is reviewed focusing on perceived stress and patients’ beliefs about it in triggering or exacerbating the course of IBD. The possible mechanisms by which stress could be translated into IBD symptoms, including changes in motor, sensory and secretory gastrointestinal function, increase intestinal permeability, and changes in the immune system are, then reviewed. The role of patients’ concerns about psychological distress and their adjustment to disease, poor coping strategies, and some personality traits that are commonly associated with these diseases are introduced. The prevalence rate, the timing of onset, and the impact of anxiety and depression on health-related quality of life are then reviewed. Finally issues about illness behavior and the necessity of integrating psychological interventions with conventional treatment protocols are explained.

1. Introduction

Inflammatory Bowel Disease (IBD) describes a group of chronic gastrointestinal tract diseases that are relapsing and remitting; the term primarily comprises Crohn’s disease (CD) and Ulcerative Colitis (UC). The prevalence of these diseases has increased in the past decades, up to 120–200/100000 and 50–200/100000 persons for UC and CD, respectively [1]. To date, there is no certain cure for IBD, and treatment is aimed at managing the inflammatory response during flares and maintaining remission with a focus on adhering to therapy [2]. The etiology of IBD is unknown, but genetic, immune, and environmental factors are each thought to play a role in its causation [1, 3, 4]. These factors interact together, so in a person who is predisposed genetically, environmental factors trigger immune dysfunction and bowel symptoms [5]. One of these environmental triggers may be psychological factors particularly psychological stress.

2. Role of Psychological Stress in IBD

A belief in the relevance of psychological factors to IBD is not new. Historically, it was first in the 1930s that gastroenterologists and psychiatrists suggested that emotional life events and experiences are likely related to exacerbation of intestinal symptoms [6]. At that time, IBD was considered as a psychosomatic disease, and its relation to stress and other psychological factors was thought so strong that researchers felt no need to use any control group in their studies. A few decades later, this finding was questioned mostly due to methodological weaknesses and uncontrolled studies published in this area. For a while IBD was considered as an organic disease, and psychological influences were discounted as contributing to it. But further anecdotal evidence and clinical observations indicated that stressful experiences could adversely affect the course of IBD.

Indeed many review articles have now emphasized the relationship between stress and IBD [6–10], concluding that confusions and controversies in published reports were partly due to differences in definitions of stress (e.g., stressful life events or hassles, daily stress) and partly due to inclusion of mixed groups of patients (CD versus UC) and/or mixed status of disease (active versus inactive) [6, 8]. Therefore, the major trends in recent studies were to differentiate between CD and UC patients, and to utilize the notion of perceived stress, which emphasizes on individual’s subjective perception of stress and his/her emotional response to it [11].

These trends have contributed to resolving controversies, and illuminating the role of psychological stress in IBD. Thus, while the role of stress in the onset of IBD has not been established, there is no doubt that stress is a triggering and exacerbating factor in relation to the course and symptoms of IBD [8, 10, 12, 13]. Indeed it can be considered as one of the determinants of disease relapse [12, 14, 15]. However, there are some discordant reports about a relation between stress and disease onset, like that of Li et al. [16] who, based on a follow-up study on the onset of IBD in parents who lost a child in Denmark, found a negative relationship between psychological stress and development of IBD. These conclusions provide support for the beliefs of almost 75% of patients with IBD that stress, or their own personality is a major contributor to the development of their disease [10, 12], and of more than 90% that it influences their disease activity [13, 17].

3. Possible Mechanisms of the Effects ofPsychological Stress on Patients with IBD

In the light of recent advances in psychobiological research, what are the mechanisms by which the course of IBD can be influenced by stress?

3.1. Nonspecific Effects

Many of the IBD symptoms experienced by patients may be due to stress-induced changes in gastrointestinal (GI) function. There is a richly innervated nerve plexus between the enteric nervous system (ENS) and its spinal and autonomic connections to the central nervous system, known as the brain-gut axis. GI motor, sensory and secretory function as well as thresholds for the perception of pain [13], can be affected by psychological and emotional stress directly or indirectly through this axis. These effects are mediated by substance P (SP), vasoactive intestinal protein (VIP) [18], several neuropeptides, neurotransmitters, and hormones [12, 19]. Stress stimulates the secretion of corticotropin-releasing factor (CRF) either from central or peripheral parts of CNS (hypothalamus and adrenal cortex, resp.). While central CRF regulates the ACTH-cortisol system, peripheral CRF directly influences gastrointestinal motility. Endogenous CRF mediates the stress-induced inhibition of the upper GI tract motility and stimulation of colonic motility [12, 20]. Thus when symptoms such as abdominal pain and change in bowel function occur in IBD without significant disease activity, they may be attributed, at least in some instances, to alterations in motor and sensory function as a result of psychological stress.

3.2. Intestinal Permeability

Psychological stress can also increase intestinal permeability, probably as a result of alterations in the cholinergic nervous system and mucosal mast cell function [21]. Söderholm and Perdue [22] pointed out that various types of physical and psychological stress have an impact on several components of intestinal barrier function such as increasing intestinal permeability and stimulating secretion of ions, water, mucus, and even IgA. This increased permeability in turn reduces mucosal barrier function and alters bacteria-host interaction [12, 23]. However, based mainly on animal studies, these observations are likely to play a role in the pathophysiology of human IBD.

3.3. Immunological Mechanisms

Finally, stress is also likely to mediate its effect on IBD through the immune system [15, 19]. On the one hand, it is believed that an inadequately controlled response within the intestinal mucosa leads to inflammation in patients who are genetically predisposed to IBD. Dysfunction of the intestinal immune system and cross-reactivity of its cells against host epithelial cells have been implicated as major mechanisms by which the inflammatory response occurs [5]. On the other hand, it is increasingly recognized that the (hypothalamus-pituarity-adrenal) HPA axis, autonomic nervous system (ANS), and ENS can interact directly with the immune system. Cytokines are essential immune molecules in the pathogenesis of IBD [24, 25]. Many researchers [15, 20, 26, 27] reported that chronic or acute stress can alter profiles of cytokines (e.g., IL-1β, IL6, IL10, IL4, and TNFα) or of hormones such as cortisol, which may contribute to the pathophysiology of IBD. There is a bidirectional communication between neurons and mast cells within the gastrointestinal tract [28], and mucosal mast cells can be activated by stress [15,29]. Stress-induced activation of mast cells, through release of mediators such as eicosanoids, serotonin, and IL6 could contribute to the pathogenesis of IBD [29].

3.4. Indirect Effects

In addition to the above-mentioned direct pathways, stress can also indirectly affect clinical course of IBD. These indirect effects are exerted through behaviors known to promote relapse [14] and include poor medication adherence [30] and smoking [31]. Direct and indirect mechanisms by which the course of IBD can be influenced by stress are shown in Figure 1.

Figure 1: Direct and indirect mechanisms by which the course of IBD can be influenced by stress.

4. Coping with IBD

Once IBD develops, the unpredictability, uncertainty, and chronic course of the disease can cause a wide range of psychological and interpersonal concerns to patients. These include loss of control of the bowel, fatigue, impairment of body image, a fear of sexual inadequacy, social isolation of dependency, a concern about not reaching to one’s full potential, and feeling dirty [13, 32]. Indeed, symptoms, such as faecal incontinence or soiling and lack of bowel control, can lead to a loss of self-unworthiness or cause stigmatization in patients [33, 34].

Dealing with these concerns needs appropriate coping strategies and good adaptation. Unfortunately, however, a variety of studies suggest that IBD patients rely significantly on passive coping strategies [34, 35], utilizing fewer purposeful problem solving and positive reappraisal, and more escape-avoidance strategies [36, 37]. Concerns such as those listed above on the one hand, and passive and/or avoidant coping on the other hand, lead to psychological distress [38] with maladaptation and poor adjustment to the disease.

Sewitch et al. [39] and Mikocka-Walus et al. [40] using Symptom Checklist-90-R (SCL-90) indicated that IBD patients had impaired psychological functioning. When patients receive a new diagnosis of IBD, a series of psychological adaptive steps occurs. For example, the patient may do an initial evaluation of the disease’s likely impact on his/her life, subsequently showing emotional reactions such as distress, grief, and sometimes guilt, exhibiting a behavioral response involving taking new medications, seeking social support, and modifying their diet; various degrees of denial and or disease acceptance may occur. This adaptive process is complex; it is likely to be influenced by a range of factors including severity of disease, age of onset of disease, its extent of interference in the patient’s life and future plans [32], beliefs and thoughts about illness and health, illness attribution [37], emotional status [41], and previous experiences.

Among these, factors such as social support and affective state (in the frame of personality trait) have been studied in detail. Sewitch et al. [39] revealed that the relationship between psychological distress and perceived stress changes according to the level of satisfaction with social support. For patients who experienced moderate-to-high levels of perceived stress, high satisfaction with social support decreased the level of psychological distress and facilitated adjustment to the disease, a point which highlights the importance of social support in maintaining mental health in and adjustment to IBD. Moreover, Pellissier et al. [41] suggested that negative effect was associated with poorer coping to IBD.

5. Personality Traits

Perhaps these factors can be integrated together and attributed to personality traits. Indeed, some patients with IBD believe that their own personality is a major contributor to the development of their disease [17]. In this context, Thornton and Andersen [42] suggest that personality traits can modulate the relationship between stress and the immunological reaction to it.

5.1. Neuroticism and Perfectionism

In IBD patients, the commonest personality trait is reported to be neuroticism [17, 43, 44]; furthermore, high neuroticism scores appear to reduce psychological wellbeing, psychological adjustment, and quality of life in patients with IBD [44, 45]. Another personality characteristic, emphasized in IBD patients, is perfectionism [46]; its negative impact in IBD is probably explained by its relationship with negative cognitive biases, heightened reactivity to stressors, and feeling pressured to be and look perfect. The latter may be particularly detrimental for IBD patients because these conditions are often accompanied by stigma, shame, feeling of dirty, and a burden [47]. The above investigators have shown a relationship between perfectionism and the psychological impact of IBD, so as the trait was associated with emotional preoccupation coping a maladaptive coping way with disease.

5.2. Alexithymia

Some studies have shown alexithymia to be another common personality characteristic in IBD patients. Patients with alexithymia have difficulty in recognizing and verbalizing emotions, and their ability to regulate emotions and express them to others is usually reduced [48]. Numerous studies [36, 44, 45, 49] have shown that IBD patients have higher scores for alexithymia than controls. In Jones, Wessinger, and Crowell’s study [36], the scores of 74 IBS patients, 55 healthy control subjects, and 48 IBD patients compared on Toronto Alexithymia Scale and results showed that the IBS and IBD patients had higher scores on measures of alexithymia than controls but did not differ from one another. Porcelli et al. [49] in an epidemiological study compared 121 functional gastrointestinal disorders patients, 116 IBD patients, and a group of 112 healthy subjects using Toronto Alexithymia Scale. Their results showed that the FGID group was significantly more alexithymic than the IBD group, and the scores of two gastrointestinal groups were higher than the normal healthy group. Even after controlling for the influence of education, gender, anxiety, depression and gastrointestinal symptoms, these differences remained significant. Moreno-Jiménez et al. [44] did not use any control group. In their sample comprised of 60 UC and 60 CD patients, they have tried to address this question that, which personality factors may predict HRQOL in IBD patients. They showed that difficulty in describing one’s feelings was significant on predicting two dimensions of HRQOL, that is, systemic symptoms and social functioning. Difficulty in describing one’s feelings negatively predicted systemic symptoms and social functioning. Patients experiencing more difficulty in describing their feelings reported lower HRQOL.

However, Drossman and Ringel [13] reemphasized that while alexithymia is not specific to IBD, it may lead patients to communicate their psychological distress through somatic and behavioral symptoms rather than verbal communication; this might occur particularly when patients have limited perceived social support or personality traits such as introversion. Whether alexithymia is specific to IBD or not, it has been reported that affected patients have greater difficulty in describing their feelings to others, have poorer disease outcome, lower psychological functioning, and worse health-related quality of life [44, 46, 50].

Although discrete personality traits have been studied among IBD patients, no certain personality type matches this disease to date. It is recommended that future research considers discrete personality traits observed in these patients and integrates them in such a way that the traits will be addressed to new personality types such as type D [51, 52] and C [53], which are well matched with unregulated immune and hormonal systems that are characteristics of IBD.

6. Anxiety and Depression

The numerous concerns and worries mentioned above, together with patients’ awareness of its incurability and uncertain course and prognosis, and their fear of surgery or the development of cancer, are all likely to contribute to a risk of anxiety in people with IBD [54, 55]. Once a patient develops IBD, he/she usually might form adaptive adjustment to it and accept the condition. Sometimes when patient has weak coping skills or social support or he/she may be personally predisposed (some personality trait such as neuroticism), he/she may feel frustrated, sad, and avoid social events. According to Seligman’s theory [56], unpredictable and incurable course of disease impaired individual’s belief about self-control [33] and self-efficacy [23, 32, 57] and thereby caused helplessness and predisposed the patient to depression.

There are some controversies about the comorbidity of clinical anxiety and depression in IBD patients. While some researchers [38, 58,59] found no evidence of any association between these psychiatric disorders and either UC or CD, others [60–63] confirmed that depression and anxiety are common in IBD patients. The prevalence of anxiety and/or depression has been estimated to be as high as 29–35% during remission [64] and 80% for anxiety and 60% for depression during relapse [65]. Robertson et al. [17] and Mikocka-Walus et al. [40] distinguished between these disorders and reported that anxiety is more prevalent than depression in IBD.

Another source of controversy lies in the question of whether psychological disorders precede and/or follow after onset of the IBD? Some researchers have considered the psychological disorders as a consequence of a new diagnosis [6, 20] and emphasized that IBD is not caused by a psychological condition. However, Kurina et al. [66], using a database of linked hospital records abstracts, in a retrospective nested case-control study on 12499 patients (7268 UC and 5231 CD) and 800000 controls with minor medical conditions not related to the conditions of interest, found that both depression and anxiety preceded UC (but not CD) significantly more often than would be predicted by chance; the relationships were strongest when the mental conditions were diagnosed shortly before UC. However, these disorders were significantly more common after the diagnosis of CD, and UC was followed by anxiety, not by depression. In contrast, Tarter et al. [67] reported that anxiety prior to diagnosis was common, in CD, but found no significant antecedent psychological disorder in UC. These researchers studied 53 consecutive IBD patients including 26 CD and 27 UC patients and 28 healthy controls. In this study compared to normal controls, CD patients manifest an increased prevalence of anxiety, depression, and panic disorder occurring at any time in their life. Only panic disorder had an excess prevalence in CD relative to community dwelling normals prior to the time of disease onset. Individuals with UC did not demonstrate an increased prevalence of psychiatric disorder before or after disease onset. Mikocka-Walus et al. [7] suggested that it is difficult to reconcile these two divergent findings, as neither study was appropriately controlled. However, the sample size of the Kurina et al.’s [66] group was substantially larger than of the Tarter et al. [67], and it is a methodological strength that partly facilitates the conclusion.

Whether anxiety and depression appear before or after the onset of IBD, physiological data [68,69], suggest that these mood disorders can stimulate production of proinflammatory cytokines and thereby adversely affect the course of IBD, a conclusion supported by clinical observations [64]. Drossman and Ringel. [13] suggest that psychological disturbances as a component of the illness may modulate its clinical expression, rather than being etiologic or specific to IBD. It is, therefore, a priority to pay careful attention to the possibility of mood disorders in patients with IBD.

7. Quality of Life (QOL)

IBD generally begins in child- or young adulthood and lasts life-long. Although the life expectancy of IBD patients approximates to that of healthy people, IBD substantially impairs patients’ health-related quality of life (HRQOL) [70, 71]. Relevant factors include those discussed above, the chronicity of IBD, its complications, associated physician visits and hospitalizations, and side effects of medical treatment or surgery. It is not surprising, therefore, those patients with active IBD have poorer disease-specific quality of life relative than those with inactive disease [35, 72–74]. Of course, poor HRQOL is not restricted to active episodes, and the negative impact of IBD on patients quality of life continues even when it is inactive. Considering disease type, Mikocka-Walus et al. [40] and Farmer et al. [75] pointed out that impairment in psychosocial dimensions of HRQOL is greater for CD than UC. Mikocka-Walus et al. [40] compared psychological problems such as anxiety and depression and impairment of quality of life in IBD, IBS and Hepatitis C, and general population. These researchers found that each of three groups had significantly lower quality of life than the general population. In IBD group, 31 participants with CD had poorer physical quality of life in Physical Component Summary (PSC) subscales of SF-12 than 33 UC patients (). Farmer et al. [75], using an interview consisted of four categories: functional/economic, social/recreational, affect/life in general, and medical/symptoms, studied quality of life on 94 patients with ulcerative colitis and 70 patients with Crohn's disease. They found that Patients with ulcerative colitis had better scores on medical/symptoms’ category in the interview than those with Crohn's disease. These researchers believed that perhaps these findings could be attributable to experiencing more severe disease by CD patients than UC patients. Drossman and Ringel [13] have pointed out to this conclusion, as well. However, others have suggested that after severity of disease was taken into account, there were no significant differences between CD and UC in terms of HRQOL [57, 70].

However, the physical symptoms of IBD do not completely explain the reductions of HRQOL in affected patients because disease activity and the intensity of patients’ symptoms do not significantly correlate with their subjective impairments [77]. Indeed, sociodemographic variables influence quality of life. For example, Sainsbury and Heatley [35], Casellas et al. [70], and Haapamaki [71] listed the effects of gender (women had poorer QOL than men), level of education, socioeconomic status, and older age on HRQOL in IBD patients. In addition to sociodemographic variables, others have noted that psychological factors can also affect HRQOL in these diseases. In this regard, more psychological disturbance and the presence of anxiety or depression contribute to poorer HRQOL, regardless of severity of the IBD [43,59, 74]. Furthermore, Moreno-Jiménez et al. [44] and Boye et al. [45] suggest that factors such as personality traits may influence psychological well-being and HRQOL; in their studies, neuroticism and greater difficulty in describing feelings to others were related to poorer HRQOL. Overall, because of its influence on patients’ psychological well-being, social adjustment to their IBD and health care utilization, integrating HRQOL into the routine clinical assessment of patients with IBD, and targeting it as a treatment aim is strongly recommended.

8. Illness Behavior

The personal meaning of the illness, the individual’s attitudes and expectations, and illness attributions to internal or external factors may all affect disease-related concerns and consequently a patient’s adjustment to an illness. Since patients differ in social context, cultural heritage, value systems, family structure, prior experiences with illness, and psychological status, each individual is likely to respond differently to the challenge of a chronic illness such as IBD. Levenstein et al. [78] suggested that because of the impact of sociocultural beliefs and values about the illness, the impact of a given disease may also vary significantly between one country and another, even if its biological behavior is uniform.

For example, a patient with ulcerative colitis who suffers from abdominal pain may not go to the physician if he/she has previously experienced those symptoms without serious consequences, or if he/she has grown up in a family where attention to illness has been minimal, or if he/she believes that complaining might be regarded as weakness. Another patient with the same disease activity and symptoms may frequently utilize healthcare services if he/she perceives symptoms to have dangerous consequences and is seeking disability or comes from a family where greater attention has been paid to illness. In this context, Drossman et al. [79] found that the number of physician visits in IBD patients was related to both psychological and physical health factors, so that the presence of psychological distress such as depression may lead to more frequent physician visits.

For the above reasons, physicians need to establish a close and effective therapeutic relationship with their patients, be sensitive and responsive to their patients’ concerns about IBD, provide information consistent with the patients’ questions and needs, and educate their patients properly about their condition and planned treatment, thereby reducing patients’ concerns and uncertainties and their dependency on the healthcare system.

9. Management of Psychological Disordersin Patients with IBD

As mentioned earlier, psychological disorders such as anxiety and depression are common among IBD patients. Even if the severity of these psychological problems does not reach the clinical definition of psychiatric disease, psychological distress, concerns, worries, fears, and poor coping strategies which may lead to reduced quality of life fully justify professional attention. Most current conventional medical treatments for IBD are associated with potential side effects, some of which are psychological (e.g., mood changes, mania, or depression induced by corticosteroids), and none of them pay attention to patient’s psychological status or concerns or QOL [63]. Therefore, integrating psychological treatment with conventional medical therapy to improve psychological distress and coping strategies and when necessary to alleviate depression or anxiety is likely to be beneficial.

9.1. Effect of Psychological Interventions on IBD Activity

It has been suggested that if psychological stress, for example, by worsening mucosal barrier and immune function, is a pathogenic factor in IBD (see above), then psychological intervention aimed at stress reduction and may potentially reduce disease activity [9, 15]. Specifically, Niess et al. [19] and Thornton and Andersen [42] proposed that psychological interventions such as relaxation training influence stress-mediated alterations of the immune system. Furthermore, psychological interventions can reportedly improve the course of some immune-mediated diseases such as cancer and HIV [93, 94]. More work is needed to assess the proposal that psychological approaches could affect the course of IBD itself.

9.2. Improving Personal Control

Another reason for incorporating these interventions as complementary options in the treatment protocol relates to establishing and highlighting for the patient a sense of personal control. Compared to medical therapy that emphasizes patient’s obedience to their doctor in relation, for example, to medication adherence, psychological interventions engage the patient in the treatment process and increase a sense of personal control of their illness. These interventions do this by educating patients about cues for managing stress and relaxing them, assist the patients to solve their problems rather than avoiding them or surrendering them to others, and restructuring their cognitions rather than trying to alter their external environment. Many researchers [95] in sociology and psychology have indicated that personal control is important to psychological functioning and can be regarded as a robust predictor of physical and mental well-being. Furthermore, psychological interventions may increase self-efficacy in patients and thereby improve their capacity for coping and managing their distress.

9.3. Potential Psychological Therapies

Numerous psychological interventions have been developed and studied in IBD, with a range of outcomes. Keller et al. [80] and Wietersheim et al. [81] reported that supportive-expressive and psychodynamic therapy may be ineffective in the treatment of psychological comorbidities and somatic course of IBD. Some studies [43,82–86] showed that although cognitive-behavioral therapy or stress management may lead to significant improvements in anxiety, depression, and quality of life, they have no effect on the course of patients’ IBD. In contrast, others [87–89] suggested that stress management, relaxation training, and IBD-focused counseling have been useful both for psychological problems and the clinical symptoms of IBD. A comprehensive lifestyle modification program [90] and mind-body therapy [91] have also been studied in IBD patients and revealed significant improvements in quality of life, anxiety, and psychological well-being.

9.4. Antidepressants

High prevalence of psychological disorders, such as anxiety and depression in patients with IBD, may recommend psychopharmacological therapies specially antidepressants as an alternative treatment for these patients. Although a qualitative study [92], based on interviewing with gastroenterologists, showed that some gastroenterologists use antidepressants for treating pain, anxiety and/or depression, and insomnia in patients with IBD, to date application of these drugs is not straightforward. Mikocka-Walus et al. [96], based on their systematic review about antidepressants and IBD, reported that tricyclic antidepressants (e.g., Amitriptylin, dothiepin, prothiaden, doxepin, imipramin, and nortriptyline) not only alleviate psychological distress, but also have some positive effects on somatic status of IBD patients through reducing pain, gut irritability, and urgency of defecation. Newer antidepressants are not prescribed as much as TCAs by physicians. Recent systematic review by Mikocka-Walus et al. [97] even reported that antidepressants have positive effect on inflammation of the bowel in IBD patients. Since the most published data in this area have not been randomized and have methodological weaknesses, Hardt et al. [63] concluded that it is impossible to make a definitive statement of efficacy of antidepressants on mental and somatic status of IBD patients.

Overall, while there are contradictory reports on the effect of psychological interventions on clinical course of IBD, most show a positive effect on psychological and emotional status and HRQOL. Contradictory findings may be in part due to difference in trial design, the components of the tested treatment protocols, outcome measures assessed, and other confounding variables. Undoubtedly, more rigorous better designed studies in this field are needed. With regard to recent findings about the effect of psychological interventions on immune modification [97, 98] and reducing the likelihood of relapse [57], the necessity of incorporating them to conventional treatment protocol of IBD is more illustrated.

10. Conclusion

Current evidence indicates that psychological factors play a role both in the pathophysiology and course of IBD and in how patients deal with these chronic and disabling diseases. Over the two last decades, improvements in study design and methodology, along with advances in psychoneuroendocrinology and psychoneuroimmunology, have led to improved, if still incomplete, understanding of the relevant pathophysiological mechanisms. The contribution of some psychological factors such as predisposing personality remains uncertain and requires further study. Most importantly, in view of the importance of psychological dysfunction in modifying illness behavior and its negative impact on symptoms and QOL, the integration of psychological interventions into conventional medical therapy, seems advisable. Where further study is most urgently needed, however, it lies in the analysis of the precise effects of these interventions on not only psychological state and quality of life, but also on the physiological parameters and the course of IBD itself. Such research should investigate also which is the most effective component, or combination of components for the psychological management of IBD.

Depression and Crohn’s Disease

Depression and the Emotional Side of Crohn's Disease

Managing Crohn's disease can be stressful and frustrating at times, but you can find ways to better manage both emotional and physical Crohn's symptoms.

By Katherine Lee

Medically reviewed by Cynthia Haines, MD

Living with Crohn’s disease and continually having to manage Crohn’s symptoms can take an emotional toll on you — and even lead to depression. But taking control of your Crohn’s can help alleviate stress and prevent or ease feelings of depression.

Crohn’s and Depression: How to Manage Emotions

When you have a chronic illness like Crohn’s, it’s important to address the emotional effects of managing your condition in addition to treating the physical symptoms. Getting Crohn’s support and becoming educated about the illness are among the most effective steps you can take.

Try these stress-management approaches, which address the stress of having Crohn’s as well as stress from other sources:

Remember that you are not alone. More than 1.4 million people in the United States are living with an inflammatory bowel disease — either Crohn’s disease or ulcerative colitis, says Jacquelyn Spencer, manager of the Information Resource Center and patient education at the Crohn's and Colitis Foundation of America (CCFA).

Learn about your illness. Knowing the facts about your disease — being aware of possible complications and being armed with information toprevent flares and treat Crohn’s symptoms — will make you feel more in control of your illness. “The more knowledge you have about your disease, the more it will reduce your stress,” says Spencer.

Do not stop your treatment. “Many people stop taking their meds when they feel well,” says Spencer. “That’s when they can experience a relapse.”

Plan ahead. Being prepared, such as having an emergency change of clothes, carrying a slim pack of wipes with you, and knowing where bathrooms are when you travel somewhere new, can go a long way toward easing anxiety.

Expect emotional turbulence. “It is not uncommon for people with Crohn’s to feel stress,” says Spencer. “There can be some depression and mood swings. In some cases, some of the meds can be the cause.” The important thing is to not let your stress get out of control. Prepare for the unexpected and take it in stride the best that you can. Practicing a stress-management technique, like meditation or deep breathing, may help you regain control.

Treat the depression. Being proactive can help you handle any depression symptoms. Lifestyle changes like exercise may help, but don’t hesitate to talk to your doctor about professional counseling, such as psychotherapy, or antidepressant medication.

Find a Crohn’s support group. “Many people tend to isolate themselves when they have Crohn’s disease,” says Spencer. “It is better to share and to realize that it is not uncommon to feel stress.” While it’s important to depend on your friends and family, there may be times when you want to talk to other people with your condition. That’s when joining a Crohn’s support group can be very useful. They can provide information and support, as well as an outlet to vent your feelings. You can attend support groups in person or join an online group through organizations like CCFA. “It’s a place where people can post personal stories,” says Spencer. “Online communities can be very important.”

Start a journal. Take time once a day, once a week, or whenever you have a spare moment and write down your thoughts. “Letting out your feelings in a notebook or journal can be very helpful,” says Spencer. You can also use this journal to recognize how different stressors in your life affect your Crohn’s symptoms.

Managing Stress to Manage Crohn’s

It’s important to get a handle on your stress for more than your emotional health — stress may actually worsen your Crohn’s symptoms. Stress can lead to adverse physiological changes even among people who do not have a chronic illness, and in times of stress, Crohn’s patients may be more likely to experience a flare-up of symptoms, such as abdominal pain and diarrhea. Severe chronic stress has also been linked to increased inflammation, and Crohn’s disease is marked by inflammation along the digestive tract.

By doing what you can to manage your stress, including sharing your feelings with a Crohn’s support group and learning more about Crohn’s disease, you can prevent and relieve some of the emotional burdens of your condition.

Sunday, September 14, 2014

Crohn's Disease VS Ulcerative Colitis

Here's some info on crohn's versus ulcerative colitis.  They have so many similarities but are completely different diseases.

*click on the pics to blow them up